The oncologist · 2026
The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial.
СтатьяКлиническое исследование I фазыКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guerrero-Ramos Félix, Gómez-Cañizo Carmen, Rodríguez-Izquierdo Marta, Hernández-Arroyo Mario, Rodríguez-Antolín Alfredo, de Velasco Guillermo, Ponce-Aix Santiago, Paramio Jesús M, Suárez-Cabrera Cristian, Rubio Carolina, Morales Lucía, García-Martínez Víctor, Dueñas Marta, Castellano Daniel
Аннотация
BACKGROUND: BladderGATE evaluated the safety, tolerability, and efficacy of intravenous (IV) atezolizumab combined with intravesical Bacillus Calmette-Guérin (BCG) in patients with BCG-naïve high-risk non-muscle invasive bladder cancer (NMIBC).
MATERIALS AND METHODS: This was a phase Ib/II open-label, nonrandomized, dose de-escalation clinical trial of atezolizumab (1200 mg IV infusion on day 1 of each 21-day cycle) plus BCG (1 instillation/week) with an induction treatment period of 6 weeks, followed by a maintenance treatment period of 52 weeks maximum. During induction, dose-limiting toxicity (DLT) and maximum tolerated dose of atezolizumab were determined. The primary study outcome was recurrence-free survival (RFS).
RESULTS: A total of 36 patients with high-risk NMIBC with a median age of 70 years were enrolled in this study. Twenty participants completed the whole treatment schedule. No DLTs were recorded during the study period. The median RFS was not reached; RFS rates were 83% (95% CI 70.6%-95.4%) and 73% (95% CI 57.4%-88.2%) at the end of the first and second year, respectively. The incidence of serious drug-related adverse events was low. Additionally, no impairment in Health-related quality of life status throughout the study was observed.
CONCLUSIONS: IV atezolizumab plus intravesical BCG in high-risk BCG-naïve NMIBC patients resulted in a high RFS rate and a manageable safety profile. These results appear consistent with those of the ALBAN study, which did not demonstrate a significant benefit of this combination over BCG alone.
MATERIALS AND METHODS: This was a phase Ib/II open-label, nonrandomized, dose de-escalation clinical trial of atezolizumab (1200 mg IV infusion on day 1 of each 21-day cycle) plus BCG (1 instillation/week) with an induction treatment period of 6 weeks, followed by a maintenance treatment period of 52 weeks maximum. During induction, dose-limiting toxicity (DLT) and maximum tolerated dose of atezolizumab were determined. The primary study outcome was recurrence-free survival (RFS).
RESULTS: A total of 36 patients with high-risk NMIBC with a median age of 70 years were enrolled in this study. Twenty participants completed the whole treatment schedule. No DLTs were recorded during the study period. The median RFS was not reached; RFS rates were 83% (95% CI 70.6%-95.4%) and 73% (95% CI 57.4%-88.2%) at the end of the first and second year, respectively. The incidence of serious drug-related adverse events was low. Additionally, no impairment in Health-related quality of life status throughout the study was observed.
CONCLUSIONS: IV atezolizumab plus intravesical BCG in high-risk BCG-naïve NMIBC patients resulted in a high RFS rate and a manageable safety profile. These results appear consistent with those of the ALBAN study, which did not demonstrate a significant benefit of this combination over BCG alone.